Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SLA Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA567335
Description
Immunogen sequence: PCLTQSTAAPA VRASSSPVTL RQKTVDWRRV SRLQEDPEGT ENPLGVDESL FSYGLRESIA SYLSLTSEDN TSFDRKKKSI SLMYGGSKRK SSFFSSPP Highest antigen sequence identity to the following orthologs - mouse 73%, rat 71%.
SLAP also known as Src-like-adapter protein 1 is a 276 amino acid containing adapter protein, functioning as a negative regulator of T-cell receptor (TCR) signaling. SLAP belonging to the SRC family of cytoplasmic tyrosine kinases contains a SH2 domain and a SH3 domain. This cytoplasmic protein colocalizes with endosomes and is known to inhibit T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. It acts as a negative regulator of positive selection and mitosis of T-cells. SLAP may act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins. Expression of SLAP is weak in heart, adult brain, placenta, liver, skeletal muscle, kidney and pancreas but is high in lung and fetal brain.
Specifications
SLA | |
Polyclonal | |
Unconjugated | |
SLA | |
hSLAP; Sla; SLA1; SLAP; Slap1; Slap-1; Src like adaptor; src-like adaptor; src-like-adapter; Src-like-adapter protein 1; Src-like-adaptor | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
6503 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunocytochemistry | |
0.2 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q13239 | |
SLA | |
Recombinant Human SLA. Recombinant protein control fragment (Product #RP-107983). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction